A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC

NCT04286958 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer

Interventions

DRUG: Camrelizumab

Sponsor

Hebei Medical University Fourth Hospital